Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb;19(2):147-149.
doi: 10.1038/s41423-021-00818-1. Epub 2021 Dec 15.

CD28 costimulation promotes an antitumor CD8+ T cell response in myeloid antigen-presenting cell niches

Jacques A Nunès  1 , Daniel Olive  2   3
Affiliations
Comment

CD28 costimulation promotes an antitumor CD8+ T cell response in myeloid antigen-presenting cell niches

Jacques A Nunès et al. Cell Mol Immunol. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JAN has no competing interests. DO is a cofounder and shareholder of Imcheck Therapeutics, Alderaan Biotechnology and Emergence Therapeutics and receives research funds from Imcheck Therapeutics, Alderaan Biotechnology, Cellectis and Emergence Therapeutics. All of these are outside of the submitted work.

Figures

Fig. 1
Fig. 1
The CD28 molecule, a license to kill delivered in myeloid APC niches. Myeloid APC niches in tumor islets contain DCs expressing CD86 (B7-2) and PD-L1. These APCs contact PD1+ CD28+ CTLA-4+ CD8+ TILs. Full activation of these TILs can be achieved by (1) blocking PD-1, (2) CTLA-4 (two immune checkpoints) and furthermore by inducing (3) APC activation that will increase the expression of CD28 ligands (B7 molecules) at their surface. This strategy focused on the CD28 molecule could optimize the ICB response in selected ovarian cancer patients. TIL tumor-infiltrating lymphocytes, TCR T cell receptor, MHC major histocompatibility complex, CTLA-4 cytotoxic T-lymphocyte-associated protein 4, PD-1 programmed death receptor 1, PD-L1 PD-1 ligand 1, GzmB granzyme B, PFN perforin
See this image and copyright information in PMC

Comment on

  • Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
    Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, Casado J, Genolet R, Benedetti F, Wicky A, Ioannidou K, Castro W, Neal C, Moriot A, Renaud-Tissot S, Anstett V, Fahr N, Tanyi JL, Eiva MA, Jacobson CA, Montone KT, Westergaard MCW, Svane IM, Kandalaft LE, Delorenzi M, Sorger PK, Färkkilä A, Michielin O, Zoete V, Carmona SJ, Foukas PG, Powell DJ Jr, Rusakiewicz S, Doucey MA, Dangaj Laniti D, Coukos G. Duraiswamy J, et al. Cancer Cell. 2021 Dec 13;39(12):1623-1642.e20. doi: 10.1016/j.ccell.2021.10.008. Epub 2021 Nov 4. Cancer Cell. 2021. PMID: 34739845 Free PMC article.

References

    1. Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm AJ, et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell. 2021;39:1–20. doi: 10.1016/j.ccell.2021.10.008. - DOI - PMC - PubMed
    1. Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, Bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39) J Clin Oncol. 2021;39:1842–55. doi: 10.1200/JCO.21.00306. - DOI - PMC - PubMed
    1. Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer. 2018;6:139. doi: 10.1186/s40425-018-0446-3. - DOI - PMC - PubMed
    1. Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2:794–802. doi: 10.1038/s43018-021-00232-6. - DOI - PMC - PubMed
    1. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355:1423–7. doi: 10.1126/science.aaf0683. - DOI - PMC - PubMed

Publication types

MeSH terms